Elicio Therapeutics, Inc. SEC filings ELTX
Elicio Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Mar 4, 2014. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jul 2, 2026 | — |
| 424B5 | Prospectus supplement | Mar 16, 2026 | — |
| S-8 | Employee stock plan registration | Mar 12, 2026 | — |
| S-3/A | Filing | Mar 12, 2026 | — |
| S-3/A | Filing | Mar 2, 2026 | — |
| S-3 | Shelf registration | Feb 27, 2026 | — |
| S-3 | Shelf registration | Nov 13, 2025 | — |
| S-8 | Employee stock plan registration | Mar 31, 2025 | — |
| 424B5 | Prospectus supplement | Jan 30, 2025 | — |
| 424B3 | Prospectus | Nov 22, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| 424B5 | Prospectus supplement | Jul 1, 2024 | — |
| 424B5 | Prospectus supplement | Jun 27, 2024 | — |
| S-3 | Shelf registration | Jun 3, 2024 | — |
| S-3/A | Filing | Jun 3, 2024 | — |
| S-8 | Employee stock plan registration | Mar 29, 2024 | — |
| S-3 | Shelf registration | Mar 29, 2024 | — |
| S-8 | Employee stock plan registration | Aug 21, 2023 | — |
| 424B3 | Prospectus | Apr 28, 2023 | — |
| S-4/A | Form s-4/a | Apr 27, 2023 | — |
| S-4/A | Form s-4/a | Apr 21, 2023 | — |
| S-4/A | Form s-4/a | Apr 13, 2023 | — |
| S-4/A | Form s-4/a | Mar 29, 2023 | — |
| S-8 | Employee stock plan registration | Mar 17, 2023 | — |
| S-4 | Registration for a merger or exchange | Feb 13, 2023 | — |
| 424B5 | Prospectus supplement | May 24, 2022 | — |
| 424B3 | Prospectus | May 24, 2022 | — |
| S-8 | Employee stock plan registration | May 16, 2022 | — |
| S-3 | Shelf registration | May 16, 2022 | — |
| S-8 | Employee stock plan registration | Feb 9, 2021 | — |
| 424B4 | Prospectus | Feb 5, 2021 | — |
| S-1/A | Amended registration statement | Feb 4, 2021 | — |
| S-1/A | Amended registration statement | Feb 1, 2021 | — |
| S-1 | Registration statement | Jan 15, 2021 | — |
| S-1/A | Amended registration statement | Aug 25, 2014 | — |
| S-1/A | Amended registration statement | May 23, 2014 | — |
| S-1 | Registration statement | Apr 14, 2014 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1601485
- Former names
- Angion Biomedica Corp. (until May 30, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.